Not a traditional drug phase: Constant Therapy program for Aphasia
The objective of this study is to apply state-of-the art brain imaging approaches to evaluate new hypotheses about the contributions of core linguistic vs. domain-general executive systems to language processing and recovery in patients with varying degrees of linguistic impairment.
Official registry: https://clinicaltrials.gov/study/NCT07926347 · Boston University Charles River Campus · enrollment listed as 100
What this phase means
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Constant Therapy program. The registry lists allocation as randomized. The objective of this study is to apply state-of-the art brain imaging approaches to evaluate new hypotheses about the contributions of core linguistic vs.
They plan to enroll about 100 people at Boston. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.
Official title (unrewritten)
Functional Reorganization and Recovery of the Language and Domain-general Multiple Demand Systems in Aphasia
Interventions: Constant Therapy program
Primary outcome (registry wording): Change in the Western Aphasia Battery Revised Aphasia Quotient
Who it is for (from inclusion criteria)
- Ages 18 Years to 80 Years
- at least 12 weeks post-stroke at time of study enrolment
- medically and neurologically stable (no active seizures for 6 months) and at least wheelchair ambulatory
- premorbid fluency in English
- a family member or caregiver available to assist in study setup and in communicating with study staff
Who the registry excludes
- a major, active neurological condition other than stroke, as determined by medical record review
- history of cognitive impairment unrelated to stroke, such as dementia
- history of symptomatic stroke prior to index stroke
- severe uncorrected vision and/or hearing problems likely to impact study participation
- comorbid learning or language disorder diagnosed prior to stroke or as a child
Public study contact (from the registry)
Swathi Kiran, PhD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- Center for Brain Recovery, BU Charles River Campus — Boston, Massachusetts (recruiting)
FAQ about this NCT record
Is NCT07926347 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07926347?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07926347?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary